Condition: Advanced Unresectable or Metastatic Breast Cancer of Adults · Sponsor: Shandong Suncadia Medicine Co., Ltd.
This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.
This description comes directly from the study's public registry record.
Yunxia Feng · +86-0518-82342973 · yunxia.feng.yf29@hengrui.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Dalian Medical University | Dalian, Liaoning, China | Recruiting |
| West China Hospital, Sichuan University | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07389733